RETRACTION

The IncRNA TUGI promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/ β -catenin pathway [Retraction]

Liu S, Liu Y, Lu Q, Zhou X, Chen L, Liang W. The lncRNA *TUG1* promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/β-catenin pathway. *OncoTargets and Therapy*. 2018:11;6845–6851.

The Editor-in-chief and Publisher of *OncoTargets and Therapy* wish to retract the published article.

Subsequent to publication, it was found the above article contained significantly similar text from several other articles: Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways by Dongli Zhang, Guixia Sun, Hongxia Zhang, Jun Tian, Yanyun Li. *Biomedicine and Pharmacotherapy*. 2017;85:511–516.

https://doi.org/10.1016/j.biopha.2016.11.058

LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis by Chuhai Xie, Binwei Chen, Boyi Wu, Jianhong Guo, Yanming Cao. *Biomedicine and Pharmacotherapy*. 2018;97:1645–1653.

https://doi.org/10.1016/j.biopha.2017.12.004

Long non-coding RNA PCAT-1 over-expression promotes proliferation and metastasis in gastric cancer cells through regulating CDKN1A by Mingjun Bi, Hongmei Yu, Bin Huang, Cuiyan Tang. *Gene*. 2017;626:337–343. https://doi.org/10.1016/j.gene.2017.05.049

LncRNA TRERNA1 Function as an Enhancer of SNA11 Promotes Gastric Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition by Huazhang Wu, Ying Hu, Xiufang Liu, Wei Song, Pihai Gong, Kun Zhang, Zhenxing Chen, Menghan Zhou, Xiahui Shen, Yanyan Qian, Hong Fan. *Molecular Therapy Nucleic Acids*. 2017;8:291–299. https://doi.org/10.1016/j.omtn.2017.06.021

Both the authors and the authors affiliated institution were contacted to provide an explanation but no response was received.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal



OncoTargets and Therapy 2019:12 1041

© 019 Dove Medical Press. This work is published and licensed by Dove Medical Press. Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creative.commons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

published authors

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes

a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from

Dovepress

1041